



FOR IMMEDIATE RELEASE
August 8, 2016

Contact: Perry Sacks
psacks@skdknick.com, 202-464-6611

Mapp Bio Receives HHS Funding for Expanded Access Protocol for Ebola Treatment

Funds Will Allow Ebola Patients Expanded Access to Experimental Treatment

SAN DIEGO – Today, Mapp Biopharmaceutical, Inc. (Mapp Bio) announced it has received funding from Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, to offer an expanded access protocol (EAP) for ZMapp™ to the four countries that participated in the PREVAIL II trial. An expanded access protocol is a U.S. regulatory mechanism for making an unlicensed drug available for the treatment of a serious or life-threatening disease for which no approved therapeutic is available. The PREVAIL II trial – sponsored by the National Institute of Allergy and Infectious Diseases (NIAID) and conducted in Liberia, Sierra Leone, Guinea and the United States – evaluated the efficacy of ZMapp™ in treating Ebola Virus Disease (EVD). While the trial did not ultimately enroll enough patients to produce definitive results, the drug was well-tolerated and showed promise in improving survival of patients with EVD.

“Mapp Bio is grateful to HHS for this funding that will allow patients suffering from Ebola to receive a promising treatment,” said Dr. Larry Zeitlin, president of Mapp Bio. “This EAP will help make ZMapp™ available while we pursue licensure.”

The EAP for ZMapp™ has been reviewed and considered safe to proceed in the U.S. by the U.S. Food and Drug Administration (FDA). Mapp Bio will make appropriate regulatory submissions in the three West African countries that participated in PREVAIL II. Mapp Bio will make ZMapp™ available to Ebola patients wishing to have access to this experimental treatment in participating countries.

Mapp Bio will continue to vigorously pursue the licensure of ZMapp™ in the U.S., and the EAP will serve to make ZMapp™ available to patients until a decision is made regarding licensure. Manufacture of the ZMapp™ that will be used for the EAP was funded by BARDA.

###

This project has been funded in whole or in part with Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under Contract Nos. HHSO100201400009C and HHSO100201600021C.”

About Mapp and Leaf Biopharmaceutical: *Mapp Biopharmaceutical was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense. The company has been developing an Ebola therapy for more than a decade and has been working with the United States and Canadian governments to develop this therapy. As these products transition to clinical evaluation, Leaf Biopharmaceutical assumes ownership and commercialization responsibilities.*